Fredrik Schjesvold, MD, PhD, Discusses the Potential of Minimal Residual Disease –Directed Treatment for Multiple Myeloma


CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.

At the 2021 International Myeloma Workshop, CancerNetwork® spoke with Fredrik Schjesvold, MD, PhD, founder and head of the Oslo Myeloma Center, about the potential of minimal residual disease (MRD)–directed treatment in multiple myeloma.


One of the things that is very actively discussed at this meeting is when, how, and if to move on to MRD-directed treatment, using MRD negativity or positivity to decide whether to move on with treatment or not. That’s being discussed on the basis of fairly little data. We don’t have any data from randomized studies saying whether that’s a good idea or not, we will know the prognostic value of MRD. There are several studies going on both in Europe and the [United States] of randomizing patients to standard or MRD-directed therapy. It’s important that we don’t establish an approach to this before we have data from these studies.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
A panel of 4 experts on multiple myeloma seated at a long table
Related Content